You are here

(NCI) Developing an Intermediate Energy Linac for Robotic Radiotherapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183390-01A1
Agency Tracking Number: R43CA183390
Amount: $264,741.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA16-019
Timeline
Solicitation Year: 2016
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-04-01
Award End Date (Contract End Date): 2016-08-31
Small Business Information
1717 STEWART ST
Santa Monica, CA 90404-4021
United States
DUNS: 140789137
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SALIME BOUCHER
 (310) 822-5845
 boucher@radiabeam.com
Business Contact
 SALIME BOUCHER
Phone: (310) 822-5845
Email: boucher@radiabeam.com
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant Robotic radiotherapy using extensively non coplanar beams has been shown effective to significantly improve radiation therapy dosimetry that leads to improved treatment outcome However current implementation of this technique by CyberKnife is inefficient and not optimal dosimetrically This has severely limited both the number of patients eligible for robotic radiotherapy and the achievable clinical outcome for those who have been treated In order to overcome these limitations we propose to develop a novel robotic radiotherapy system that can efficiently utilize the full potential of the non coplanar delivery space to treat the majority of radiotherapy patients Innovation The proposed system is highly innovative in the following aspect Integrated beam orientation and fluence optimization Significantly more compact linac to allow posterior beams Flexible field sizes
and MLC resolution to efficiently treat most target sizes Integrated volumetric imaging system This project is proposed to design a hardware platform materializing such robotic radiotherapy system In order to reduce the gantry size both the linac length and the distance between the source and the MLC need to be significantly reduced We propose to design a new MV source to reduce linac length and provide the required dose rate for treatment The physical MLC leaf thickness cannot be substantially thinner than mm To achieve a high MLC resolution at the treatment distance a spacer is used in CyberKnife between the primary collimator and the MLC increasing the gantry dimension We propose to eliminate the spacer but vary the focus to tumor distances FTD to achieve desired field size and MLC resolution This requires optimization in an enormous solution space a capacity uniquely demonstrated by the p algorithm Volumetric imaging has been an indispensable component of modern radiotherapy but unfortunately missing from existing robotic systems The proposed new linac will be able to deliver kV imaging beams from the same MV linac which in combination with gantry or couch mounted imagers will allow volumetric imaging for more precise tumor targeting Aims Prototypical design of the accelerator to produce MV X rays Design incorporated imaging system Develop a conceptual design for the entire clinical system Impact Success of the Phase I project would lead to the design of the first MV linear accelerator capable of producing a competitively high dose rate of andgt cGy min at cm and kV imaging beams for image guided radiotherapy This paves the technical path to a new robotic radiotherapy system delivering radiation plans with dose conformality surpassing existing X ray platforms More importantly the significantly increased field size throughput and the volumetric imaging capacity would allow the new robotic system to compete for a much larger market including that for conventional linacs than the niche market CyberKnife currently commands

PUBLIC HEALTH RELEVANCE Success of the proposed project would lead to the development of a novel radiation therapy device capable of significantly reducing the radiation dose deposited to healthy tissue during cancer treatment The final clinical system to be developed in Phase II would revolutionize the field of radiation therapy by allowing this precise tumor targeting to be achieved with a quick flexible robotic system enabling high patient throughput This system is expected to manage a wide range of diseases and treatment fractions thus having a broad clinical and commercial impact

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government